CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the members of the management team will present at upcoming conferences. The presentation details are as follows:
- Rodman & Renshaw® Annual Global Investment Conference on Tuesday, September 10, 2013 at 10 a.m. ET at the Millennium Broadway Hotel in New York City, NY
- 2013 US-Japan Health Sciences Dialogue; Market Hot-Spot: Highlight on Oncology, Where is the Action and Why? on Tuesday, September 10, 2013 at 3:00 p.m. ET at the Union League of Philadelphia, Philadelphia, PA
- Baird Healthcare Conference on Wednesday, September 11, 2013 at 9:05 a.m. ET at The New York Palace Hotel in New York City, NY
- Stifel Nicolaus Healthcare Conference on Wednesday, September 11, 2013 at 1:30 p.m. ET at The Four Seasons Hotel in Boston, MA
Webcasts of the Rodman & Renshaw, Baird Healthcare and Stifel Nicolaus presentations can be accessed by visiting the investors section of the Company’s website at www.verastem.com. Replays of each of the webcasts will be archived on the Verastem website for 30 days following the presentation date.
About Verastem, Inc.
Verastem, Inc. (NASDAQ: VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.
Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.